Fennec Pharmaceuticals Inc. · NASDAQ:FENC
Fennec Pharmaceuticals — Investor Presentation (August 2026)
31 slides from Fennec Pharmaceuticals's investor presentation, August 2026
Slide 1: Corporate Presentation August 2026
Corporate Presentation August 2026 WWW.FENNECPHARMA.COM FEN-1321-v15 1
Slide 2: Safe harbor statement
Safe harbor statement Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to id
Slide 3: Fennec is changing the sound of cancer care
Fennec is changing the sound of cancer care Transforming Cancer Care Expanding Global Footprint with PEDMARK® • European partnership with • The first and only FDA- Norgine approved therapy for cisplatin- • Japan registration induced ototoxicity (CIO)*: preparation underway • Endorsed in NCCN treatme
Slide 4: Survival should be loud
M AY I N C LU D E P E R M A N E N T H E A R I N G LO S S They rang the bell. But some couldn’t hear it. Survival should sound like something. A voice you love, a laugh breaking through. That’s the promise they fought for. But an asterisk creeps in. It quiets the victory for 60-90% of cancer survivor
Slide 5: Cisplatin: A Cornerstone of Modern Cancer Care – with a Caveat
Cisplatin: A Cornerstone of Modern Cancer Care – with a Caveat If the price of curing a childhood cancer patient is permanent hearing loss, we haven’t fully healed the child > Dr. F, Pediatric Oncologist, Academic Institution CONFIDENTIAL INFORMATION - For intended audiences only. Do not copy or dis
Slide 6: Cisplatin is an indispensable component of treatment
Cisplatin is an indispensable component of Pediatric1 Adolescents and Young Adults (AYA)1 treatment Neuroblastoma Testicular Cancer Medulloblastoma Breast Cancer Overall survival rates Hepatoblastoma Bladder Cancer for some cancers treated with cisplatin can reach upwards of 87%1,2 Osteosarcoma Cerv
Slide 7: Despite its effectiveness, cisplatin causes irreversible hearing loss
Despite its effectiveness, cisplatin causes irreversible hearing loss 60% to 90% of patients treated with cisplatin may develop hearing loss2-4 Common Clinical Presentation of Hearing Loss Cisplatin Induced Ototoxicity (CIO) • High frequency (≥4 kHz) sensorineural hearing loss1,2 – Bilateral (both e
Slide 8: Damage can start early—often within just one or two cycles
Damage can start early—often within just one or two cycles FREQUENCY IN KHZ • Ototoxicity is a cisplatin dose-limiting 0.125 0.25 0.5 1 1.5 2 3 4 6 8 10 toxicity1 meaning that efficacy of 0 chemotherapy could be compromised due to ototoxicity management 20 • Effects can be seen as soon as the HEARIN
Slide 9: The Unseen Burden
The Unseen Burden I didn’t know there was the possibility of permanent hearing loss; the muffled and sometimes high-pitched, shrill reminder that something in me broke and won’t be fixed. > Katy M., Cancer Survivor & Audiologist 9 CONFIDENTIAL INFORMATION - For intended audiences only. Do not copy o
Slide 10: Tinnitus & hearing loss: the iceberg model
Tinnitus & hearing loss: the iceberg model Auditory Component1: • Ringing in the ears1 • Difficulty hearing1 • Decreased sound tolerance1 Non-Auditory Component1: • Avoidance of social settings1 • Isolation1 • Chronic stress1 • Anxiety, depression, PTSD1 • Insomnia1 Other components include: Communi
Slide 11: Hearing loss changes how patients live, learn, and connect
Hearing loss changes how patients live, learn, and connect You just want the cancer to be over with. The hearing loss is a constant reminder of the worst two years of my life and a permanent mark that the cancer left on me. Patients with hearing Hearing loss impacts many loss resulting from aspects
Slide 12: For decades, oncologists had no way to prevent CIO
For decades, oncologists had no way to prevent CIO Management through treatment modifications that could impact survival, or management of hearing loss when treatment has been completed: Speech Hearing Aids1 Rehabilitation3 Personal Frequency Modulation Cochlear (FM Classroom Implants1 Amplification
Slide 13: Financial impact of severe to profound hearing loss
Financial impact of severe to profound hearing loss can be considerable across a patient’s lifespan1 48% $1M 1 $489,274 Loss of Productivity Lifetime cost of hearing loss can exceed USD 29% Lifetime cost for individuals Educational Costs *Based on 2023 USD with early onset of severe to profound hear
Slide 14: No Proven Protection — Until Now
No Proven Protection — Until Now This is the kind of innovation that reminds us that cancer care isn’t just about survival. It’s about living well after. > Dr. P., Pediatric Oncologist, Academic Institution 14 CONFIDENTIAL INFORMATION - For intended audiences only. Do not copy or distribute. MED-FEN
Slide 15: Proven protection. Established safety. Consistent benefit.
PEDMARK® (sodium thiosulfate injection): Clinically proven to reduce the risk of hearing loss without compromising cancer treatment The first and only therapy approved in the U.S. to reduce the risk of ototoxicity associated with cisplatin in pediatric patients ≥1 month of age with localized, non-me
Slide 16: National guidelines affirm the importance of preventing hearing loss in AYA patients
National guidelines affirm the importance of preventing hearing loss in AYA cancer patients with 2A recommendation Guidelines recommend sodium NCCN CATEGORY 2A Recommended thiosulfate (PEDMARK), the NCCN Guidelines for AYA Oncology only FDA-approved treatment recommends sodium thiosulfate (PEDMARK)
Slide 17: In the pediatric population, the need for hearing protection extends across geographies
In the pediatric population, the need for hearing protection extends across geographies 6,785 4,650 Annual Incidence of Pediatric Solid Tumor Cases in Both U.S. and EU Markets* Top Three Tumor Types: Neuroblastoma, CNS & Osteosarcoma U.S. MARKET EUROPEAN MARKET 2,157 1,250 Cisplatin-Treated Patients
Slide 18: 90% of U.S. pediatric cancer patients receive care at ~200 top centers
90% of U.S. pediatric cancer patients receive SEATTLE care at ~200 top Insert Map with MINNEAPOLIS Minneapolis centers nationwide DETROIT Detroit Cities/States BOSTON Highlighted NYC CHICAGO PHILADELPHIA Institutions LOS ANGELES RALEIGH • ~200 target pediatric hospital DALLAS centers, including COG,
Slide 19: Adolescent and young adult solid tumors remain a significant challenge in the U.S.
In the adolescent and Annual Incidence of AYA young adult population, Solid Tumor Cases in solid tumors remain the U.S.* 58,985 a significant challenge Insert Map with in the U.S. Cities/States Highlighted U.S. MARKET 25,536 Cisplatin-Treated Patients with Non- Metastatic Solid Tumors PEDMARK® MARKE
Slide 20: AYA cancer care spans the nation—led by academic centers
AYA cancer care Community Centers Academic Centers Across the U.S. Across the U.S. spans the nation— led by academic centers, delivered in Insert Map with community practices Cities/States Highlighted Academic Institutions Play Critical Role in Establishing Treatment Landscape • 72 NCI-designated ac
Slide 21: A Clear Path to Impact and Value Creation
A Clear Path to Impact and Value Creation Fennec is helping to change the standard of care for protecting the hearing of cancer patients receiving cisplatin treatment in ways we never could before. > Dr. B., Medical Oncologist, Community Practice 21 CONFIDENTIAL INFORMATION - For intended audiences
Slide 22: Focused strategy. Scalable opportunity.
Focused strategy. Scalable opportunity. Strategic imperatives driving the strategy and execution for PEDMARK include: Awareness: Standard of Adoption: Access: Increase awareness Care (SOC): Build lasting trust Ensure advocacy, around unmet patient Establish PEDMARK as through exceptional payers & pr
Slide 23: Building awareness, access, and advocacy in the U.S.
Building awareness, access, and advocacy in the U.S. New Campaign Promotion Market Access Access & Patient Support • Digital and in-person • Large oncology network adoption • Fully revamped Fennec HEARS promotional resources patient services program • P&T and formulary resources for • Peer-to-peer s
Slide 24: Expanding global footprint to ensure greater access to PEDMARK
Expanding global footprint to ensure greater access to PEDMARK® Europe • Norgine has Japan successfully launched PEDMARQSI® • Positive topline results from in Germany, England the investigator-initiated and Wales in 2025 clinical trial (STS-J01) in Japan evaluating PEDMARK® were • Norgine launching
Slide 25: Generating clinical evidence to support wider use of PEDMARK
Generating clinical evidence to support wider use of PEDMARK® Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce CIO Focused medical affairs efforts are • Study met primary endpoint with a significant reduction in hearing loss with advancing new data t
Slide 26: Independent investigators driving clinical research with PEDMARK
Independent investigators driving clinical research with PEDMARK® • City of Hope, a U.S. cancer research and treatment organization, is evaluating use of PEDMARK® in adult men with stage II-III metastatic testicular germ cell tumors • Tampa General Hospital Cancer Institute is evaluating the real-wo
Slide 27: Education, access & reimbursement support
Education, access & reimbursement support Insurance-Related Support: Patient Assistance Program: Quick Start Program: • Benefits investigation, prior • Provides eligible patients with • New patients experiencing delays authorization, and/or appeal process access to free product in in determining cov
Slide 28: Capital structure and financial information
FENNEC | Capital structure and financial information Stock Listings Current FENC – Nasdaq FRX – TSX, Canada 35.1M $17.1M Shares Outstanding1 2026 Q2 Net Product Sales2 $41.2M $2.8M Cash and Cash Equivalents1 2026 Q2 Non-GAAP Adjusted EBITDA2,3 Fennec rings the closing NASDAQ Bell in September 2025 s
Slide 29: PEDMARK Product Revenue Summary
PEDMARK® Product Revenue Summary 7 quarters of consecutive revenue growth $17.1 $15.1 OCT 2024 New Executive $13.8 Leadership $12.5 $9.7 $8.8 $7.9 $7.4 $7.3 $7.0 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 29
Slide 30: Indications and important safety information
Indications and important safety information INDICATION & USAGE Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical o
Slide 31: Thank you
Thank you PEDMARK® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc. Fennec HEARS is a trademark of Fennec Pharmaceuticals Inc. ©2023 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1321-v15 May 2026 31 31
Fennec Pharmaceuticals — Investor Presentation (August 2026) on 6ix